 |
 |
Aegera Therapeutics Inc. - Nun's Island, Québec
Aegera Therapeutics is building an integrated world-class biotechnology company focused on signal transduction and apoptosis.
Learn more about...
www.aegera.com
|
 |
Agrisoma BioSciences Inc. - Burnaby, British Columbia
Agrisoma Biosciences Inc. "Agrisoma" is a private Canadian biotechnology company developing a chromosome-based gene delivery and expression technology in plant systems, to enable the development of value enhanced crops and the production of industrial and therapeutic proteins.
Learn more about...
www.agrisoma.com |
 |
AngioChem - Laval, Québec
Developer of therapeutics for central nervous systems disease (cancer and others). The mission is to become a world leader in the field of Central Nervous System (CNS) Oncology following the development and commercialization of novel technologies and therapeutics from research on the cerebrovascular endothelium. In the long term, AngioChem is looking to extend its positioning in the overall field of CNS diseases using its technology with various chemotherapeutic or bio-therapeutic agents.
www.angiochem.com |
 |
AnorMed Inc. - Langley, British Columbia
AnorMED's core strength involves the application of chemistry, biochemistry and biology to the discovery and development of small molecule therapeutics for the treatment of diseases including HIV, inflammation and cancer.
Learn more about...
www.anormed.com
|
 |
Aurelium BioPharma Inc. - Montréal, Québec
Aurelium BioPharma Inc. is the therapeutics company using an integrated Suite of leading-edge proteomics tools that integrate validated targets and complementary diagnostics to deliver therapeutic solutions rapidly and cost effectively. Their SMART TM proteomics covers several enabling and proprietary technology platforms that allows the company to rapidly identify and validate a large number of druggable protein targets. Aurelium's immediate focus is the development therapeutics and diagnostic tools for the treatment of drug-resistant cancers, for which there is currently no treatment available.
Learn more about...
www.aureliumbiopharma.com |
 |
Bioniche Life Sciences Inc. - Belleville, Ontario
Bioniche Life Sciences Inc. has evolved into a research-based, technology-driven Canadian biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. Key areas of strategic focus for Bioniche include developing effective therapies for bladder cancer (Phase II/III) and potentially other cancers; a cattle vaccine to help prevent E. coli O157:H7 infection; technologies to improve reproduction and potentially replace the use of antibiotics in livestock.
Learn more about...
www.bioniche.com |
 |
Bioriginal Food & Science Corporation - Saskatoon, Saskatchewan
Bioriginal is the world's leading supplier of essential fatty acid (EFA) oils, including fish, flax, borage (starflower), evening primrose, black currant and perilla, as well as CLA. Delivery systems range from bulk oils and softgels to finished, packaged products.
www.bioriginal.com |
 |
Biorthex Inc. - Montréal, Québec
Biorthex is an orthopedic device manufacturer that develops, manufactures and markets innovative spinal interbody fusion devices and instruments for the treatment of degenerative conditions of the human spine.
Learn more about...
www.biorthex.com
|
 |
BioSyntech Canada Inc. - Laval, Québec
BioSyntech - Established in 1995 and traded on the TSX Venture since 2004, BioSyntech has created and developed innovative biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery, which appeal to large unsatisfied markets.
Learn more about...
www.biosyntech.com |
 |
Celator Pharmaceuticals Inc. - Vancouver, British Columbia
Formerly Celator Technologies, Inc., Celator is a biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies designed to target cancer cells.
www.celator.ca |
 |
CellFor Inc. - Victoria, British Columbia
CellFor is the world's first and only commercial supplier of eleite varietal conifer seedlings to the forestry industry.
Learn more about...
www.cellfor.com |
 |
Chromos Molecular Systems Inc.- Burnaby, British Columbia
Chromos Molecular Systems Inc. is a public Canadian biotechnology company leading the development of innovative therapies using a proprietary gene delivery and expression system for the production of therapeutic proteins and cell-mediated gene therapies in the treatment of disease.
Learn more about...
www.chromos.com |
 |
ConjuChem Inc. - Montréal, Québec
ConjuChem is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company's primary focus is the further development of a drug for Type 2 diabetes, which is currently in Phase II testing.
Learn more about...
www.conjuchem.com |
 |
Cytochroma Inc. - Markham, Ontario
Cytochroma Inc. is a leader in the discovery of cytochrome P450 genes, the identification of the function of the proteins encoded by those genes, and the discovery of highly potent and specific drugs regulating cytochrome P450 enzymes to address unmet medical needs.
Learn more about...
www.cytochroma.com |
 |
Gemin X Biotechnologies Inc. - Montréal, Québec
Gemin X specializes in the discovery and development of novel therapeutics that modulate apoptosis, the body's natural ability to destroy diseased or damaged cells, in life-threatening diseases.
Learn more about...
www.geminx.com |
 |
Inflazyme Pharmaceuticals Ltd. - Richmond, British Columbia
Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammation and other related diseases. Our core focus is medicinal chemistry based small molecules aimed at treating unmet medical needs specifically in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as well as other inflammatory disorders.
Learn more about...
www.inflazyme.com
|
 |
Inimex Pharmaceuticals Inc.- Vancouver, British Columbia
Inimex Pharmaceuticals Inc. is focused on the development of new medicines that utilize the innate immune response to prevent or treat human disease. Inimex has identified and patented novel prospective lead peptide drug candidates that treat and prevent infections based on a novel approach that will overcome the issues of drug resistance. Inimex medicines selectively activate elements of host innate immunity to combat infection. By enhancing innate immunity rather than acting directly against bacteria, these compounds will not promote microbial resistance. www.inimexpharma.com |
 |
Innodia Inc. - Laval, Québec
Innodia Inc. is a biotechnology company engaged in taking to the market novel drugs for the treatment of type 2 diabetes and related diseases and in generating value for its shareholders.
www.innodia-inc.com |
 |
Interface Biologics Inc. - Toronto, Ontario
Interface Biologics' goal is to continuously design innovative biomaterials that will bring about the delivery of successful health care products to world markets. This is being achieved through the application of novel polymer technologies adept at responding to the interface between material structure and human host response. Interface Biologics has an integrated approach to solving mechanical and biological problems by designing the solution within the biomaterial. This unique approach allows for a diverse range of products with specific properties to be produced faster, more uniformly, and at a lower cost.
www.interfacebiologics.com |
 |
Ionalytics Corporation - Ottawa, Ontario
Ionalytics Corporation designs and manufactures the Ionalytics Selectra, an accessory for mass spectrometers that significantly reduces background chemical noise and provides unique ion separation capability. The Selectra, which can be attached to existing or new mass spectrometers, is currently being used within drug discovery markets in both pharmaceutical and proteomics applications.
www.ionalytics.com |
 |
Kytogenics Pharmaceuticals Limited - Dartmouth, N.S.
Kytogenics Pharmaceuticals is a biomedical company engaged in the development of products based on its medical device and drug delivery proprietary platform technologies. Their Phase III Clinical Trial for the reduction of gynaecological post-surgical adhesions, its most advanced medical device product, has been initiated. Kytogenics' oral delivery of peptides is its most exciting opportunity in the drug delivery area. Strategic alliances have been entered into with major healthcare companies.
www.kytogenics.com |
 |
LMS Medical Systems Limited - Montréal, Québec
LMS is the leader in the use of advanced mathematical modeling and neural networks to provide real time obstetrical decision guidance at the patient bedside. LMS is committed to reducing the risks involved with childbirth and to improving pregnancy outcomes for women and their fetus.
Learn more about...
www.lmsmedical.com |
 |
LymphoSign Inc. - Markham, Ontario
LymphoSign's approach to cancer therapy is based on targeting signal transduction pathways which lead to aberrant cell growth found in cancer. Drugs which act in this way constitute a new class called "targeted therapeutics". Targeted therapies can be developed against receptors, genes and proteins in cellular signaling pathways which support cancer cell growth. Targeted therapies have advantages over traditional chemotherapy in that they inhibit cancer cells but have low toxicity to normal cells and tissues thus avoiding the severe side effects common in traditional chemotherapy treatments of cancer.
Learn more about...
www.lymphosign.com
|
 |
Methylgene Inc.- Montréal, Québec
MethylGene Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel and proprietary enzyme inhibitors for the treatment of cancer and infectious diseases.
www.methylgene.com |
 |
Millenium Biologix Corporation - Kingston, Ontario
Millenium Biologix Corporation is a biomedical company focused on the development and commercialization of next generation orthobiologic and skeletal tissue regeneration products that promote the repair and natural healing of human bone and other tissues.
Learn more about...
www.millenium-biologix.com |
 |
Monteris Medical Inc. - Winnipeg, Manitoba
The mission of Monteris Medical Inc. is to develop a device and a procedure that allows hospitals, clinics and others to provide their patients and themselves with an economical and effective alternative to conventional treatments for metastatic and primary tumors.
www.monteris.com |
 |
Neurochem Inc. - Laval, Québec
Neurochem is committed to developing innovative pharmaceutical products for neurological disorders that offer significant benefits to human health and quality of life, particularly for Alzheimer's disease, hemorrhagic stroke (due to cerebral amyloid angiopathy), AA Amyloidosis as well as a variety of other amyloid-related diseases and disorders of the central nervous system.
www.neurochem.com |
 |
NeuroMed Technologies Inc.- Vancouver, British Columbia
Launched in 1998, NeuroMed is a biopharmaceutical company focused on the development of small molecule drugs targeting neuronal calcium channels to treat neurological disorders, with the initial emphasis on chronic pain, anxiety and stroke.
Learn more about...
www.neuromedtech.com |
 |
Novadaq Technologies Inc. - Mississauga, Ontario
Novadaq™ Technologies develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseases and conditions. Novadaq's SPY Intra-operative Imaging System enables surgeons to visually assess coronary vasculature and bypass graft functionality during the course of CABG surgery. Novadaq's ophthalmic product, the OPTTX™ System, is aimed at the diagnosis and treatment of Wet Age Related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The OPTTX System is currently in clinical development.
www.novadaq.com |
 |
Oncogenex Technologies Inc. - Vancouver, British Columbia
OncoGenex is a biotechnology company focused on the development of therapeutics for cancer. The first products developed by the company are for the treatment of advanced and untreatable prostate cancer, responsible at that stage of the disease for the majority of patient deaths.
Learn more about...
www.oncogenex.ca |
|
 |
Osprey Pharmaceuticals Limited -
Montréal, Québec
Osprey Pharmaceuticals is developing a series of proprietary therapeutics that selectively kill cells involved in the initiation and continuation of inappropriate inflammation: the origin of many acute and chronic diseases.
Learn more about...
www.ospreypharmaceuticals.com |
 |
PainCeptor Pharma Corporation - Montréal, Québec
Painceptor maintains a leadership position in the development of safe, effective and peripherally-active pharmaceuticals for the treatment and management of pain. Painceptor's researchers and industrial collaborators have advanced a series of highly selective organic molecules which will alleviate pain in a number of debilitating untreated diseases. PainCeptor's therapeutics relieve pain by intercepting tissue specific pain at the source and promoting a receptive physiological environment for relief of chronic and acute pain.
www.painceptor.com |
 |
Protiva Biotherapeutics Inc. - Burnaby, British Columbia
Protiva Biotherapeutics is a development stage biotechnology company, focused on pharmaceutical products to fight against cancer and inflammatory disease. Protiva's technology, employing liposomes to encapsulate and deliver genes, allows therapeutic proteins to be produced by the body and act selectively at sites of disease.
Learn more about...
www.protivabio.com |
 |
Resonant Medical Inc. - Montréal, Québec
Resonant Medical Inc. researches, develops and markets 3D ultrasound image-guided adaptive radiotherapy products. Resonant's goal is to enable fundamental improvements to radiation oncology treatment planning, verification and delivery.
Learn more about...
www.resonantmedical.com |
 |
SemBioSys Genetics Inc. - Calgary, Alberta
SemBioSys Genetics Inc. is a biotechnology company focused on the development, commercialization and production of protein-based pharmaceuticals and non-pharmaceutical products based on our plant genetic engineering skills and our proprietary oilbody-oleosin technology platform - the Stratosome Biologic System.
www.sembiosys.ca |
 |
Topigen Pharmaceuticals Inc. - Montréal, Québec
Privately-held, Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its proprietary platform technology using novel, DNA/RNA chemistry. These drugs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This pioneering approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis (AR).
www.topigen.com |
 |
Tranzyme Pharma Inc. - Durham, North Carolina, Sherbrooke, Québec
Tranzyme Pharma is a leading biopharmaceutical company developing novel small molecule therapeutics for the treatment of gastrointestinal (GI) diseases. The Company's candidate drugs originate from its own discovery pipeline of proprietary compounds with high affinity for validated and "druggable" targets in the GI tract. Tranzyme's unique clinical focus is on diseases associated with severe dysfunctional motility of the GI tract. Tranzyme is developing first-in-class, mechanism-based therapeutic candidates directed at ghrelin (responsible for upper gut motility, appetite regulation, and energy balance) and motilin (responsible for regulation of GI transit). Clinical indications for these compounds include GI diseases such as post-operative ileus (POI), diabetic gastroparesis, irritable bowel syndrome-diarrhea-type (IBS-d), and functional dyspepsia.
www.tranzyme.com |
 |
Trillium Therapeutics Inc. - Toronto, Ontario
Trillium Therapeutics Inc. is a research and development company specializing in innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses. These include autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases. TTI identifies early-stage therapeutic candidates with promising preclinical profiles and advances these towards clinical testing, with the primary objective of demonstrating safety and efficacy in humans.
www.trilliumtherapeutics.com |
 |
ViroChem Pharma Inc.- Montréal, Québec
ViroChem Pharma Inc. focuses on the discovery and development of antiviral therapeutic agents. The company is product-oriented and R&D based. Its strategy is to maintain a result-oriented equilibrium between risk and probability of success by focusing selectively on druggable biological targets that are well validated with small molecule lead(s) but do not yet have adequate drug therapies in the market.
www.virochempharma.com
|
 |
Victhom Human Bionics - Port Coquitlam, British Columbia
Victhom develops human bionic devices. Victhom's objective is to improve the quality of life of people suffering from physical dysfunctions. When considered appropriate, Victhom acquires technologies and businesses that provide the company with a strategic advantage in the pursuit of its development programs and corporate objectives. Victhom's core expertise lies in its capability to develop biomechatronic medical devices and to eliminate technology risks. Victhom teams up with multinational companies for the commercialization of its technologies.
www.victhom.com |
 |
Xillix Technologies Corp. - Richmond, British Columbia
Xillix is focused on the research, development and commercialization of medical imaging technologies which aid in the early detection and localization of cancer.
www.xillix.com |
 |
YM BioSciences, Inc. - Mississauga, Ontario
YM BioSciences Inc., the cancer product development company, was established in Canada in 1994. Its drug development portfolio, which includes three products in clinical development, is based on technologies licensed principally from academic centres of excellence internationally.
Learn more about...
www.ymbiosciences.com |
 |
Zelos Therapeutics Inc. - Ottawa, Ontario
Zelos Therapeutics Inc. is an early-stage therapeutics product development company. Established in 2001, Zelos is advancing technology for the treatment of osteoporosis, psoriasis and other diseases based on research initiated at Canada's National Research Council (NRC). The Company is privately held, and has commenced Phase II for its first product, Ostabolin-C™, for the treatment of osteoporosis.
www.zelostherapeutics.com |
|
